Previous 10 | Next 10 |
Source If valuing a company was as easy as attaching an intrinsic value based on an investor ratio such as price-to-earnings or price-to-cash flow, or even a discounted cash flow method, it would have been really difficult to lose money in the stock market. Numbers, most certainly, play an...
CytoDyn ( CYDY ) is an exciting stock, never more so than recently. This article reviews its late developments. CytoDyn's majestic rise from $0.30 has been a thing of beauty spreading wealth to savvy biotech investors. CytoDyn has taken savvy investors on a dream ride over the last nine ...
VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, anno...
CytoDyn ( OTCQB:CYDY ) has entered into a Memorandum of Understanding (MoU) with the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals of Mexico (NIH) to conduct a COVID-19 clinical trial with leronlimab for severe and critically ill patients, w...
VANCOUVER, Washington, June 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
Cytodyn ( OTCQB:CYDY ) is a triple threat or more with one drug, leronlimab. HIV First, is its work on HIV over the past years. Over 800 patients were tested, and since it blocks the CCR5 receptor which is HIV’s known point of entry, it works very well. A BLA (biologics license ap...
The silver lining in the persistence of COVID-19 infections, at least for some investors, is the bullish outlook for companies developing vaccines and/or therapies for the respiratory infection. More news on: Vir Biotechnology, Inc., Dynavax Technologies Corporation, Novavax, Inc., Healthc...
COVID-19 traveled around the world spreading fear, devastation and death in a world that was caught unprepared. The United States' response to this worldwide pandemic has been highly reactive and has left many citizens angry and disoriented. People want things to move on. Many, if not most, ...
Let everyone follow his own belief, for, as you know, there is an immense variety of opinions and freedom of judgement. - Petrarch, Secretum In July, Cytodyn (CYDY) is facing a key binary event, two readouts on the COVID-19 trials it initiated back in April. Strong positive results on ...
ENDRA Life Sciences Inc. (NDRA) recently announced it is moving forward with the commercialization of its Thermo Acoustic Enhanced UltraSound (TAEUS) device in Europe. The TAEUS device is essentially a point of care ((POC)) or field diagnostic hybrid of an ultrasound and MRI that can monitor...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...